CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
XagenaNewsletter
Onco News

Search results for "Entresto"

A 8-week, multicenter, open-label study has assessed the safety and efficacy of LCZ696 ( Entresto ), a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension ...


The PARADIGM-HF ( Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure ) trial has demonstrated that a new angiotensin receptor antagonist - ...


The angiotensin-receptor-neprilysin inhibitor ( ARNI ) Valsartan / Sacubitril ( Entresto; LCZ696 ) reduced cardiovascular deaths and all-cause mortality compared with Enalapril in patients with chroni ...


A post-hoc analysis of PARADIGM-HF data has demonstrated that fewer heart failure patients with reduced ejection fraction ( HFrEF ) treated with Entresto ( Sacubitril / Valsartan ) tablets were readm ...


The combination drug Valsartan / Sacubitril known as LCZ696 ( Entresto ) significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker ( ...


European Society of Cardiology ( ESC ) Guidelines for the diagnosis and treatment of acute and chronic heart failure are published in European Heart Journal and the European Journal of Heart Failure, ...


A study assessed whether the benefit of Sacubitril / Valsartan ( Entresto ) therapy varied with clinical stability. Despite the benefit of Sacubitril / Valsartan therapy shown in the PARADIGM-HF ( ...


The quality of evidence regarding patient-centered outcomes in adults with heart failure after Sacubitril combined with Valsartan ( Entresto ) has not been systematically appraised. An analysis ha ...


Sacubitril / Valsartan ( Entresto ) has been shown to improve mortality and reduce hospitalizations in patients with heart failure with reduced ejection fraction ( HFrEF ). The effect of combination ...


Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany ) has shown that Entresto ( Sacubitril / Valsartan ) can be initiated early and safe ...


Because neprilysin is involved in the degradation of amyloid-beta, there is concern that the angiotensin-neprilysin inhibitor Sacubitril - Valsartan ( Entresto ) could increase the risk for dementia. ...


Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction ( HFrEF ), as shown in PARADIGM-HF which compared ...


Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of Sacubitril - Valsartan ( Entresto ) therapy is safe and eff ...


The results from the global phase III PARAGON-HF study, investigating the safety and efficacy of Sacubitril / Valsartan ( Entresto ) versus the active comparator Valsartan in HFpEF ( heart failure wit ...